Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.

Clinical responses to ERK inhibition in BRAF V600E-mutant colorectal cancer predicted using a computational model

Open access

Abstract

Approximately 10% of colorectal cancers harbor BRAFV600E mutations, which constitutively activate the MAPK signaling pathway. We sought to determine whether ERK inhibitor (GDC-0994)-containing regimens may be of clinical benefit to these patients based on data from in vitro (cell line) and in vivo (cell- and patient-derived xenograft) studies of cetuximab (EGFR), vemurafenib (BRAF), cobimetinib (MEK), and GDC-0994 (ERK) combinations. Preclinical data was used to develop a mechanism-based computational model linking cell surface receptor (EGFR) activation, the MAPK signaling pathway, and tumor growth. Clinical predictions of anti-tumor activity were enabled by the use of tumor response data from three Phase 1 clinical trials testing combinations of EGFR, BRAF, and MEK inhibitors. Simulated responses to GDC-0994 monotherapy (overall response rate = 17%) accurately predicted results from a Phase 1 clinical trial regarding the number of responding patients (2/18) and the distribution of tumor size changes (“waterfall plot”). Prospective simulations were then used to evaluate potential drug combinations and predictive biomarkers for increasing responsiveness to MEK/ERK inhibitors in these patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41540-017-0016-1

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 MAPK signaling model structure and development workflow. a Model structure. Gray nodes indicate core MAPK signal signaling components, blue nodes represent regulatory feedback components, and white nodes surrogate alternate pathway (PI3K/Akt), alternate receptors (RTK2, 3), and signal integration (S6) components. b Model development workflow, highlighting data inputs (gray boxes), pre-clinical modeling tasks (blue boxes), and clinical translation modeling tasks (red boxes), and associated figures. PSO particle swarm optimization, LSE least squares estimation
Fig. 1 MAPK signaling model structure and development workflow. a Model structure. Gray nodes indicate core MAPK signal signaling components, blue nodes represent regulatory feedback components, and white nodes surrogate alternate pathway (PI3K/Akt), alternate receptors (RTK2, 3), and signal integration (S6) components. b Model development workflow, highlighting data inputs (gray boxes), pre-clinical modeling tasks (blue boxes), and clinical translation modeling tasks (red boxes), and associated figures. PSO particle swarm optimization, LSE least squares estimationCC BY · PubMed Central
Fig. 2 The MAPK model reproduces published in vitro signaling and drug sensitivity data. pERK dynamics in response to BRAFi treatment in EGFRlo melanoma cells a and EGFRhi CRC cells b. c Degree of pERK ‘‘rebound’’ with the three potential feedback mechanisms switched on in isolation, and simultaneously, error bars indicating std across parameter sets. d Simulated cell growth (fold expansion) over 72 h for six variant cell lines with six drug treatments. Asterisks indicate conditions with matching data.18, 23, 32 e Relationship between steady-state pMEK and pERK. Gray lines are simulations of 20 alternate model parameter sets; blue line is a simulation of the Schoeberl (2002) mechanism-based biochemical model,34 and red dots are quantitative western blot data from four BRAF-CRC cell lines treated with the pan-RAFi AZ628 (ref. 32). f Viability of four BRAF-CRC cell lines cultured in the presence (red) or absence (blue) of TGF-α, HGF, or FGF ligands. Thick lines indicate median responses
Fig. 2 The MAPK model reproduces published in vitro signaling and drug sensitivity data. pERK dynamics in response to BRAFi treatment in EGFRlo melanoma cells a and EGFRhi CRC cells b. c Degree of pERK ‘‘rebound’’ with the three potential feedback mechanisms switched on in isolation, and simultaneously, error bars indicating std across parameter sets. d Simulated cell growth (fold expansion) over 72 h for six variant cell lines with six drug treatments. Asterisks indicate conditions with matching data.18, 23, 32 e Relationship between steady-state pMEK and pERK. Gray lines are simulations of 20 alternate model parameter sets; blue line is a simulation of the Schoeberl (2002) mechanism-based biochemical model,34 and red dots are quantitative western blot data from four BRAF-CRC cell lines treated with the pan-RAFi AZ628 (ref. 32). f Viability of four BRAF-CRC cell lines cultured in the presence (red) or absence (blue) of TGF-α, HGF, or FGF ligands. Thick lines indicate median responsesCC BY · PubMed Central
Fig. 3 MAPKi sensitivity profiles of CRC cell lines. a Sensitivity (mean viability) of 14 CRC cell lines to EGFR, BRAF, MEK, and ERK inhibition. b Median differences in sensitivity (mean viability) between the seven sensitive (S) vs. seven resistant (R) cell lines to 15 drugs, including five MAPK pathway inhibitors, five inhibitors of other signaling pathways, and five cytotoxic chemotherapies. c Cell viability dose–responses of 14 cell lines to vemurafenib, cobimetinib, and GDC-0994. Cell lines are annotated as relatively MAPKi sensitive (blue) vs. resistant (red), overlying individual cell line data (light lines) and model simulations (thick lines). c Normalized sensitivity (z-scored mean viability) of nine CRC and 37 melanoma cell lines to GDC-0994 cobimetinib and vemurafenib
Fig. 3 MAPKi sensitivity profiles of CRC cell lines. a Sensitivity (mean viability) of 14 CRC cell lines to EGFR, BRAF, MEK, and ERK inhibition. b Median differences in sensitivity (mean viability) between the seven sensitive (S) vs. seven resistant (R) cell lines to 15 drugs, including five MAPK pathway inhibitors, five inhibitors of other signaling pathways, and five cytotoxic chemotherapies. c Cell viability dose–responses of 14 cell lines to vemurafenib, cobimetinib, and GDC-0994. Cell lines are annotated as relatively MAPKi sensitive (blue) vs. resistant (red), overlying individual cell line data (light lines) and model simulations (thick lines). c Normalized sensitivity (z-scored mean viability) of nine CRC and 37 melanoma cell lines to GDC-0994 cobimetinib and vemurafenibCC BY · PubMed Central
Fig. 4 HT29 xenograft tumor growth kinetics over 21 days. Individual tumors (thin lines) and model simulations (thick lines) overlaid, with plots color-coded as: untreated control (black), treatment data used for model training (blue), and model predictions, i.e., data not used for training (red and pink, corresponding to double and triple drug combinations)
Fig. 4 HT29 xenograft tumor growth kinetics over 21 days. Individual tumors (thin lines) and model simulations (thick lines) overlaid, with plots color-coded as: untreated control (black), treatment data used for model training (blue), and model predictions, i.e., data not used for training (red and pink, corresponding to double and triple drug combinations)CC BY · PubMed Central
Fig. 5 Tumor growth and treatment responses in HT29 cell-line derived xenografts vs. two PDX models, CR1472 and CRC15. a HT29 vs. CR1472 and b HT29 vs. CRC15 tumor growth over 21-days on 13 alternate treatments. c Model simulations and experimental observations of changes in tumor size over 21-days for the 13 treatments
Fig. 5 Tumor growth and treatment responses in HT29 cell-line derived xenografts vs. two PDX models, CR1472 and CRC15. a HT29 vs. CR1472 and b HT29 vs. CRC15 tumor growth over 21-days on 13 alternate treatments. c Model simulations and experimental observations of changes in tumor size over 21-days for the 13 treatmentsCC BY · PubMed Central
Fig. 6 Simulated pharmacokinetics and tumor responses on 16 drug treatment regimens. a Simulated serum drug concentrations for cetuximab, vemurafenib, cobimetinib, and GDC-0994 dosed at clinical regimens. Median, 5 and 95-percentiles are shown in black lines. b Relative changes in tumor size following two cycles of treatment (8 weeks) on all 16 possible combinations of the four drugs, for prevalence weighted model simulations (gray) and clinical data (red). c Simulated ORRs for baseline tumors (RTK2lo), and those with RTK2 set at 15% that of EGFR (RTK2med)
Fig. 6 Simulated pharmacokinetics and tumor responses on 16 drug treatment regimens. a Simulated serum drug concentrations for cetuximab, vemurafenib, cobimetinib, and GDC-0994 dosed at clinical regimens. Median, 5 and 95-percentiles are shown in black lines. b Relative changes in tumor size following two cycles of treatment (8 weeks) on all 16 possible combinations of the four drugs, for prevalence weighted model simulations (gray) and clinical data (red). c Simulated ORRs for baseline tumors (RTK2lo), and those with RTK2 set at 15% that of EGFR (RTK2med)CC BY · PubMed Central
Fig. 7 Clinical trial simulations and data for GDC-0994 monotherapy, and combination with cobimetinib. a Simulated tumor size changes (waterfall plots), and data from 13 evaluable patients treated with GDC-0994. b Simulated distribution of expected responses for an 18 patient clinical trial, gray bar indicating clinical results (2/18). c Simulated ORR to combinations of cobimtenib and GDC-0994
Fig. 7 Clinical trial simulations and data for GDC-0994 monotherapy, and combination with cobimetinib. a Simulated tumor size changes (waterfall plots), and data from 13 evaluable patients treated with GDC-0994. b Simulated distribution of expected responses for an 18 patient clinical trial, gray bar indicating clinical results (2/18). c Simulated ORR to combinations of cobimtenib and GDC-0994CC BY · PubMed Central
Fig. 8 Enhancement of GDC-0994/cobimetinib responses via biomarker stratification or combination with additional anti-cancer agents. Simulated tumor responses (waterfall plots), and cobimetinb x GDC-0994 combination surface responses for a, b patients selected with greater than the 50-percentile MAPK-dependence, and c, d combination with another anti-cancer agent that increases the rate of cell death by 10% independent of MAPK signaling
Fig. 8 Enhancement of GDC-0994/cobimetinib responses via biomarker stratification or combination with additional anti-cancer agents. Simulated tumor responses (waterfall plots), and cobimetinb x GDC-0994 combination surface responses for a, b patients selected with greater than the 50-percentile MAPK-dependence, and c, d combination with another anti-cancer agent that increases the rate of cell death by 10% independent of MAPK signalingCC BY · PubMed Central
Fig. 9 Relative sensitivity (z-scored mean viability) to BRAF, MEK, and ERK inhibition by indication. Cancer cell lines were separated by tissue type and mutational status (RAS = KRAS, HRAS or NRAS mutant, RAF = BRAF-mutant, WT = RAS/RAF wild type), and median values computed for each
Fig. 9 Relative sensitivity (z-scored mean viability) to BRAF, MEK, and ERK inhibition by indication. Cancer cell lines were separated by tissue type and mutational status (RAS = KRAS, HRAS or NRAS mutant, RAF = BRAF-mutant, WT = RAS/RAF wild type), and median values computed for eachCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 75 references

Research works printed but not linked: 1

  1. Larkin, J. et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med. 371, 1867–1876 (2014). · DOI · Paper page

Cited by

See all 67

Metadata

Authors
Kirouac, D. C., Schaefer, G., Chan, J., Merchant, M., Orr, C., Huang, S.-M. A., Moffat, J., Liu, L., Gadkar, K., & Ramanujan, S.
Affiliations
Genentech (US)
Corresponding author
Ramanujan, Saroja
Venue
npj Systems Biology and Applications
Published
2017-06-02
Volume
3
Issue
1
Pages
14-14
ISSN
2056-7189 (ISSN-L)
OpenAlex
W2618321737
Cited by
60
References
75
Citations by year
2026: 3 · 2025: 4 · 2024: 7 · 2023: 6 · 2022: 8 · 2021: 9 · 2020: 7 · 2019: 11 · 2018: 5
FWCI
2.77
Type
journal article
Language
en
Update notices
erratum (2017-09-04)
Open access
Licence
Locations
  • npj Systems Biology and Applications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
Keywords
BRAF V600E mutation, colorectal cancer, ERK inhibition, MAPK signaling, EGFR inhibition, vemurafenib, cobimetinib, cetuximab, combination therapy, predictive biomarkers, drug response prediction, patient-derived xenografts

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical responses to ERK inhibition in BRAF V600E-mutant colorectal cancer predicted using a computational model. https://app.cochat.ai/papers/10.1038/s41540-017-0016-1
The paper
Kirouac, D. C., Schaefer, G., Chan, J., Merchant, M., Orr, C., Huang, S.-M. A., Moffat, J., Liu, L., Gadkar, K., & Ramanujan, S. (2017). Clinical responses to ERK inhibition in BRAF V600E-mutant colorectal cancer predicted using a computational model. npj Systems Biology and Applications. https://doi.org/10.1038/s41540-017-0016-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.